Study explores fitness training approach during breast cancer treatment in multi-sport athlete

NewsGuard 100/100 Score

Professional athletes undergoing treatment for cancer often are in the headlines. Yet, details of their training during such treatment rarely are disclosed. In this study, an elite multi-sport female athlete was followed to learn her training approach to keeping her 'competitive edge' while being treated for stage III breast cancer.

Over 32 months, the research team monitored her fitness levels while she received chemotherapy, surgery, radiotherapy and breast reconstruction. Her most pronounced decline in fitness occurred after chemotherapy, while she had smaller declines following surgery and radiation. This athlete did recover her pre-treatment fitness due to a combination of factors - persistence, a realistic training regimen and regular communications between her medical care providers and exercise physiologist. Given the importance of fitness on survival in breast cancer patients, this case-report should inspire and motivate both sedentary and highly active women cancer patients, as they recover their fitness and their lives.

Source: American College of Sports Medicine (ACSM)

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer